Validation of a new neuropsychological test for processing speed
Validation and Standardization of the Consecutive-Letter Substitution Task (CST) Test in an Italian Population Sample
This study is testing a new brain test to see how well it measures how quickly people can process information, using healthy volunteers from Italy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 480 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | IRCCS San Raffaele Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06066281 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate the Consecutive-Letter Substitution Task (CST), a neuropsychological test designed to measure information processing speed. Healthy volunteers from the Italian population will undergo a series of standardized neuropsychological assessments, including the CST and other established tests, to compare their effectiveness. Participants will complete the CST twice, with a follow-up evaluation after 15 days to assess the test's reliability. The study is conducted at a single center, IRCCS San Raffaele in Milan.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy Italian native speakers with no neurological or psychiatric diseases.
Not a fit: Patients with a history of substance abuse or significant depressive symptoms may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a validated tool for assessing cognitive processing speed, which may improve diagnosis and monitoring of conditions like multiple sclerosis.
How similar studies have performed: While the CST is a novel approach, similar neuropsychological tests have shown success in validating cognitive assessments.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Italian native speaker; * No neurological and/or psychiatric diseases; * Willing and able to comply with study procedures. Exclusion Criteria: * History of drug, alcohol or substance abuse; * A score \> 9 on the Montgomery-Åsberg Depression Rating Scale (MADRS), which is the lower limit for mild depressive symptoms; * Any person unable to understand and follow the instructions of the investigators.
Where this trial is running
Milan
- IRCCS San Raffaele — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Massimo Filippi, MD — IRCCS San Raffaele
- Study coordinator: Massimo Filippi, MD
- Email: filippi.massimo@hsr.it
- Phone: 00390226433054
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.